Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection. Its mechanism of action involves inhibiting the HIV-1 reverse transcriptase enzyme, which is crucial for the replication of the HIV virus. By binding to an allosteric site on the reverse transcriptase enzyme, doravirine causes conformational changes that prevent the enzyme from converting viral RNA into DNA, thereby interfering with the subsequent steps of the viral replication cycle.
Doravirine is often used in combination with other antiretroviral agents to achieve better efficacy in suppressing HIV viral loads and improving patient outcomes. It has shown significant effectiveness in reducing HIV-1 RNA levels in clinical trials and is considered an important component of antiretroviral therapy regimens.
